Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Cytokinetics Inc shares valued at $117,843 were purchased by EDWARD KAYE on Jun 05 ’25. At $32.41 per share, EDWARD KAYE acquired 3,636 shares.
Also, Kaye Edward M. MD sold 3,636 shares, netting a total of over 116,716 in proceeds. Following the sale of shares at $32.10 each, the insider now holds 29,658 shares.
Before that, Callos Andrew had sold 8,659 shares from its account. In a trade valued at $277,434, the EVP, Chief Commercial Officer traded Cytokinetics Inc shares for $32.04 each. Upon closing the transaction, the insider’s holdings decreased to 8,659 shares, worth approximately $1.72 million.
As published in their initiating research note from Barclays on April 24, 2025, Cytokinetics Inc [CYTK] has been an Overweight and the price target has been revised to $55. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in early February. As of January 22, 2025, Stifel has initiated its “Buy” rating for CYTK. Earlier on November 08, 2024, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for CYTK stock.
Analyzing CYTK Stock Performance
During the last five days, there has been a surge of approximately 2.16%. Over the course of the year, Cytokinetics Inc shares have dropped approximately -29.61%. Shares of the company reached a 52-week high of $52.80 on 01/27/25 and a 52-week low of $29.31 on 05/15/25.
Support And Resistance Levels for Cytokinetics Inc (CYTK)
According to the 24-hour chart, there is a support level at 32.55, which, if violated, would cause prices to drop to 31.98. In the upper region, resistance lies at 34.15. The next price resistance is at 35.18. RSI (Relative Strength Index) is 49.82 on the 14-day chart, showing neutral technical sentiment.
